Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Sheffield Teaching Hospitals NHS Foundation Trust
With
AstraZeneca
University of Sheffield
University of Dundee
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
People with eosinophilic asthma meeting the National Institute for Health and Clinical Excellence (NICE) criteria for benralizumab therapy based on eosinophil count and exacerbation rates will be offered the chance to participate in this study.
You may not be if
Any medical illness that in the opinion of the investigator is likely to significantly impact on the response to benralizumab or the outcome of the MRI and lung function testing.
Non-concordance with routine asthma therapies (this would be assessed as a mandatory part of NICE-based criteria).
Current cigarette smoking, or cigarette smoking within the past 6 months
Significant lifetime smoking history of ≥20 pack years
Previous use of another biologic therapy targeting eosinophils within 6 months of enrollment
Pregnancy, planning pregnancy, or breast feeding. Women of childbearing potential must use effective contraception (concordant use of hormonal contraceptive, intrauterine device, total abstinence), and urine pregnancy tests will be performed before scans.
Abnormal renal function (eGFR \<30), to avoid risks from Gadolinium chelate MRI contrast agents.
Clareo Health | MRI and Lung Function Measures of Benralizumab Response in Asthma
